



Cover art: Neil Webb

Editorial

Herb Brody, Richard Hodson, Elizabeth Batty, Jenny Rooke, Nick Haines

Art & Design

Mohamed Ashour, Andrea Duffy, Denis Mallet

Production

Nick Bruni, Karl Smart, Ian Pope, Kay Lewis

Sponsorship

David Bagshaw, Claudia Danci

Marketing

Nicole Jackson

Project Manager

Rebecca Jones

Creative Director

Wojtek Urbanek

Publisher

Richard Hughes

VP, Editorial

Stephen Pincock

Managing Editor

David Payne

Magazine Editor

Helen Pearson

Editor-in-Chief

Magdalena Skipper

Carlos Heras-Palou was a 39-year-old surgeon with two young daughters when he developed hereditary transthyretin (hATTR) amyloidosis, a rare degenerative disease caused by the misfolding of a protein called transthyretin (TTR). That diagnosis in 2004 carried a grim prognosis: a typical life expectancy of 3 to 15 years. At the time, most people who developed hATTR amyloidosis needed to be treated with transplant surgery. But another option emerged. Heras-Palou and his younger sister Isabel, who was diagnosed with the condition in 2013, enrolled in studies for a drug that thwarts production of the toxic protein by binding to messenger RNA — the molecule that carries genetic instructions for producing TTR.

Approval of this drug and one other by US and European regulators in 2018 (see page S7) has given fresh impetus to the nascent research field after more than a decade of false starts. That development has raised hopes that RNA therapies in their various forms (S2) can treat not only rare conditions (S16) but also more common ones, including treatments for cardiovascular disease (S13) and vaccines for cancer (S10).

More than a dozen RNA therapies are currently being tested in clinical trials. But major challenges remain, most notably in how to deliver therapeutic strands of RNA into the right cells (S8). Progress will depend on a continuing commitment from pharmaceutical companies to drive and fund innovation (S4). Researchers also need to up their game when it comes to communicating the underlying science of gene manipulation in all its complexity to patients and the wider public (S15).

We are pleased to acknowledge the financial support of Ionis Pharmaceuticals in producing this Outlook. As always, *Nature* retains sole responsibility for all editorial content.

David Payne

Managing Editor, Nature Careers and Supplements

CONTENTS

S2 TREATMENT

RNA therapies explained

The three main approaches

S4 DRUG DISCOVERY

Pharma's RNA roller coaster

The ups and downs of RNA interference

S7 PERSPECTIVE

Patisiran's path to approval

Carlos Heras-Palou explains his part in the drug's approval

S8 RNA INTERFERENCE

Strand and deliver

The difficulty of delivering therapy

S10 VACCINES

Injection of hope

Messenger RNA could boost immunity

S13 HEART DISEASE

RNA therapy sets sail for the heart

Could it work for cardiovascular disease?

S15 PERSPECTIVE

Eclipsed by CRISPR

It is time to shout about RNA therapies, says Lorna Harries

S16 THERAPEUTICS

A tale of two drugs

Rare diseases under the spotlight

Nature Outlooks are sponsored supplements that aim to stimulate interest and debate around a subject of interest to the sponsor, while satisfying the editorial values of *Nature* and our readers' expectations. The boundaries of sponsor involvement are clearly delineated in the *Nature Outlook* Editorial guidelines available at go.nature.com/e4dwzw

CITING THE OUTLOOK

Cite as a supplement to *Nature*, for example, *Nature* Vol. XXX, No. XXXX Suppl., Sxx–Sxx (2019).

VISIT THE OUTLOOK ONLINE

The *Nature Outlook RNA therapies* supplement can be found at www.nature.com/collections/ma-therapy-outlook. It features all newly commissioned content as well as a selection of relevant previously published material that is made freely

available for 6 months.

SUBSCRIPTIONS AND CUSTOMER SERVICES

Site licences (www.nature.com/libraries/site_licences): Americas, institutions@natureny.com; Asia-Pacific, <http://nature.asia/jp-contact>; Australia/New Zealand, nature@macmillan.com.au; Europe/ROW, institutions@nature.com; India, npgindia@nature.com. Personal subscriptions: UK/Europe/ROW, subscriptions@nature.com; USA/Canada/Latin America, subscriptions@us.nature.com; Japan, <http://nature.asia/jp-contact>; China, <http://nature.asia/china-subscribe>; Korea, www.natureasia.com/ko-kr/subscribe.

CUSTOMER SERVICES

Feedback@nature.com

Copyright © 2019 Springer Nature Ltd. All rights reserved.